DOCS

ANALYST NOTE: DOCS (Doximity, Inc.) Date: 2026-06-13 Current Price: $20.46

1. Structural Readiness

State: Context-Only (No defined structural coil identified in the provided data stream). Conservative Entry: — Breakout Level: — Extension: — ATR Current: 4.9% (High)

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Macro Thesis: None. Assessment: There is no named secular macro thesis attached to this name as of this date. The investment case must be judged strictly on the quality of the business fundamentals and the readiness of the technical setup (which is currently undefined). We are not assigning a "growth at a reasonable price" or "AI disruption" label as a primary driver; rather, we are evaluating the company based on its current operational metrics and the specific guidance provided by management. The conviction stack relies entirely on the strength of the earnings data and the structural quality of the price action once defined.

3. The Business

Company Overview: Doximity, Inc. operates a digital platform hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. The platform delivers specialized tools for peer connection, patient treatment streamlining, remote consultations, and professional career advancement. Business Model: The company generates revenue primarily from pharmaceutical manufacturers and health systems. These customers access a suite of commercial solutions that leverage the platform's broad usage by physicians and other medical professionals. Key Fundamentals (as of 2026-06-13):

• Revenue Growth: For the nine months ended December 31, 2025, revenue was $499.5 million, up 16% year-over-year from $432.1 million. For the three months ended December 31, 2025, revenue was $185.1 million, up 10% year-over-year.
• Guidance (FY 2027): Management expects full-year revenue of $664 million to $676 million (4% growth at midpoint) and adjusted EBITDA of $323 million to $335 million (49% margin).
• Customer Base: The company serves more than 85% of U.S. physicians. Nearly half of all U.S. doctors work at hospitals that buy Doximity's workflow or scheduling tools.
• AI Integration: As of March 31, 2026, 140 health systems have adopted the Clinical AI Suite. In the 9 months since acquiring Pathway, AI Search and Scribe active users have tripled.
• Retention: Net revenue retention rate is 112% to 117%. The cohort of customers with at least $500,000 of revenue accounted for approximately 84% of TTM revenue.
• AI Strategy: Management has forecasted "minimal AI revenue contribution" for the current fiscal year, noting that AI investments (R&D, compute, marketing) will weigh on near-term margins. However, they believe AI search represents a "multibillion dollar new TAM" and have closed early deals with top 20 pharma manufacturers.

4. Archetype and Conviction

Archetype: Quality Compounder / Margin Inflector (with near-term investment drag). Rationale: The company exhibits characteristics of a high-quality compounder with dominant market share (85% of physicians) and strong retention (112-117%). The business model is shifting toward a "margin inflector" profile, with management guiding for 49% adjusted EBITDA margins. However, the archetype is currently tempered by a deliberate "investment phase" where management is prioritizing AI infrastructure and R&D over immediate revenue recognition, explicitly stating that these expenses will weigh on near-term margins. Valuation Context: The financial spine indicates a forward consensus EPS of $1.5465 for FY1 and $1.43286 for FY2. Conviction Stack:

• Thesis Strength: Low (No named macro thesis; purely tactical).
• Evidence Quality: High (Strong earnings data, clear guidance, dominant market metrics).
• Setup Readiness: Low (Price action structure is undefined).
• Rerating Potential: Moderate (Dependent on the successful monetization of the AI suite and the realization of the 49% margin guidance).

ATR Context: The current ATR of 4.9% falls into the "High" bucket (4–6%). Historically, this is a "sweet spot" for volatility, suggesting sufficient liquidity and movement for position sizing, but it also indicates elevated price sensitivity.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Management updating guidance to reflect earlier-than-expected AI revenue contribution (moving beyond "minimal").
• Continued expansion of the "Clinical AI Suite" adoption beyond the current 140 health systems.

What Would Invalidate the Case:

• Management guidance for FY 2027 revenue growth falling below the 4% midpoint or EBITDA margins compressing significantly below the 46-49% range.
• A decline in the Net Revenue Retention rate below 110%.

Gaps in Evidence:

• AI Revenue Specifics: While management mentions "early innings" and "multibillion dollar TAM," specific dollar figures for AI revenue contribution remain vague, described only as "minimal" for the current fiscal year.
• Capex Details: The specific magnitude of the "higher R&D, compute and marketing spend" is not quantified in the provided evidence, making it difficult to model the exact margin impact.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: 1) Dominant market position with 85% physician penetration and 112-117% net revenue retention. 2) Clear guidance for 49% adjusted EBITDA margins in FY 2027. 3) Strong adoption of Clinical AI Suite with 140 health systems and tripled active users since Pathway acquisition. Expected path: Management expects to absorb higher R&D and compute costs to build the AI infrastructure, with revenue growth stabilizing at 4% and margins expanding to 49% as the AI suite scales. Expected horizon: 12-18 months for the AI investment cycle to mature into revenue contribution. Failure mode to watch: A sustained close below the current price level ($20.46) combined with a downgrade in FY 2027 margin guidance, indicating the AI investment is not yielding the expected structural efficiency.